Alliance for Regenerative Medicine Promotes Michael Lehmicke to Senior Vice President, Science & Industry Affairs
July 19, 2023
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the promotion of Michael Lehmicke to Senior Vice President, Science & Industry Affairs, effective immediately.
Proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorized in the EU
June 20, 2023
Without changes recognizing the unique characteristics of ATMPs, the EU’s new Joint Clinical Assessment will fail to deliver the next generation of transformative therapies to rare disease patients, according to the Alliance for Regenerative Medicine, EveryLife Foundation for Rare Diseases, and Rare Diseases International.